Curis Pharmaceuticals says it has halted enrollment in an early stage trial of an experimental skin cancer therapy, citing potential problems with skin absorption. Curis has decided not to go ahead with the therapy as it is currently formulated and will decide in the next few months how it wants to proceed. Curis is partnered with Genentech on the development of the therapy.
"We currently are sharing in the development costs for this clinical candidate and we expect that our co-development expenditures will decline in the short term pending determination of the future basal cell carcinoma development plan," said Daniel R. Passeri, president and chief executive of Curis Inc, in a statement.
- here's the AP report on Curis